AirSculpt Technologies (NASDAQ:AIRS) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

AirSculpt Technologies (NASDAQ:AIRS) released its quarterly earnings results on Friday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05), FiscalAI reports. AirSculpt Technologies had a negative net margin of 7.79% and a negative return on equity of 5.83%. The company had revenue of $31.94 million during the quarter, compared to analyst estimates of $34.33 million.

Here are the key takeaways from AirSculpt Technologies’ conference call:

• Negative Sentiment: Third-quarter results fell short: revenue declined 8.7% year over year, same-center case volume fell 9.6%, and adjusted EBITDA dropped to about $0.4 million from $3 million. Management attributed the weakness to lower marketing productivity and operational challenges at several centers.
• Negative Sentiment: Google’s AI Overviews reduced traffic reaching AirSculpt’s website, contributing to 16% fewer leads and a 26% higher cost per lead; customer acquisition cost rose to about $3,800 per case from $3,100. Management said it is working to improve AI-search visibility and expand local marketing, but noted those efforts may take time to affect revenue.
• Negative Sentiment: AirSculpt cut its 2026 outlook, now expecting revenue of $144 million–$146 million versus $151 million–$157 million previously, and adjusted EBITDA of $9 million–$10 million versus $12 million–$14 million. The revised forecast assumes third-quarter trends continue through Q4.
• Positive Sentiment: GLP-1-related procedures reached 250 in the quarter, nearly 10% of total cases, and are now offered in almost all centers. Management sees a potential $100 million-plus long-term revenue opportunity, while acknowledging that these newer services require tailored marketing and patient education.
• Positive Sentiment: The company refinanced its debt with a $44 million facility maturing in 2031, extending its maturity and providing more covenant and payment flexibility; quarter-end liquidity was about $20 million. The new loan carries an interest rate roughly 300 basis points above the prior facility.

AirSculpt Technologies Stock Performance

Shares of NASDAQ:AIRS traded down $0.91 on Friday, reaching $0.53. The company had a trading volume of 11,073,870 shares, compared to its average volume of 828,261. The stock has a 50-day moving average price of $1.87 and a 200 day moving average price of $3.08. AirSculpt Technologies has a twelve month low of $0.52 and a twelve month high of $8.09. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.79 and a quick ratio of 0.79.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AirSculpt Technologies in a research report on Monday, September 28th. Lake Street Capital initiated coverage on shares of AirSculpt Technologies in a research note on Thursday, October 29th. They set a “buy” rating and a $3.00 price target on the stock. Finally, Wall Street Zen downgraded shares of AirSculpt Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.75.

About AirSculpt Technologies

AirSculpt Technologies, Inc operates a medical aesthetics business focused on body-contouring and cosmetic procedures. Through its AirSculpt brand, the company provides minimally invasive liposuction and fat-transfer treatments designed to remove unwanted fat and reshape areas of the body.

Its services also include procedures such as skin tightening and other elective aesthetic treatments, with offerings varying by location and patient needs. AirSculpt markets its procedures directly to consumers and provides consultations, treatment planning and follow-up care through its network of company-operated centers.

The company was founded in 2015 by plastic surgeon Dr.